Drug Trial Radar · NCT06396039
A Study to Assess the Effectiveness and Safety of Ozanimod in Chinese Adults With Relapsing Multiple Sclerosis
Last checked: Nov 20, 2026Latest source record: Apr 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
84
Planned (sponsor's estimate)
Start
May 15, 2024
Primary completion
Dec 29, 2028
Study completion Mar 30, 2029
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- May 2, 2024
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the effectiveness and safety of ozanimod in Chinese adults with relapsing multiple sclerosis.
Conditions
- Relapsing Multiple Sclerosis
Interventions
BMS-986374Drug
Specified dose on specified days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Annualized relapse rate (ARR) over 36 monthsTime frame: Up to 3 years
Locations
25 sites in 1 country. Site status is shown where the registry gives one.
Local Institution - 0009
Beijing, China
Local Institution - 0025
Fuzhou, China
Local Institution - 0010
Guiyang, China
Local Institution - 0013
Hohhot, China
Local Institution - 0014
Shanghai, China
Local Institution - 0021
Shenyang, China
Local Institution - 0001
Tianjin, China
Local Institution - 0020
Xianyang, China
Local Institution - 0002
Beijing, Beijing Municipality, China
Local Institution - 0012
Guangzhou, Guangdong, China
Local Institution - 0022
Guangzhou, Guangdong, China
Local Institution - 0008
Shenzhen, Guangdong, China
Local Institution - 0004
Shijiazhuang, Hebei, China
Local Institution - 0006
Harbin, Heilongjiang, China
Local Institution - 0018
Zhengzhou, Henan, China
Local Institution - 0007
Wuhan, Hubei, China
Local Institution - 0003
Nanchang, Jiangxi, China
Local Institution - 0005
Changchun, Jilin, China
Local Institution - 0015
Taiyuan, Shan1xi, China
Local Institution - 0023
Ürümqi, Shan1xi, China
Local Institution - 0016
Shanghai, Shanghai Municipality, China
Local Institution - 0011
Chengdu, Sichuan, China
Local Institution - 0024
Kunming, Yunnan, China
Local Institution - 0019
Hangzhou, Zhejiang, China
Local Institution - 0017
Wenzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.